Human Autologous Lung Stem Cell Transplant for Idiopathic Pulmonary Fibrosis

Exclusion Criteria

• •Diagnosis of an interstitial lung disease (ILD) or restrictive lung disease other than IPF or Progressive Fibrotic Interstitial Lung Disease.
• •Obstructive lung disease as determined by evidence of airflow obstruction on HRCT or physiologic criteria including: FEV1/FVC ratio less than 0.75, Residual volume (RV) greater than 120% by plethysmography or significant (verified by radiologist) emphysema on HRCT or evidence of reactive airway disease by change in FEV1 of greater than 12% following bronchodilator challenge.
• •Evidence of sustained improvement lung function defined as improvement from pre-therapy pulmonary function tests (PFTs) observed with two or more successive post-therapy PFTs over the year prior to randomization.
• •Active or recent (less than 60 days prior to enrollment) significant respiratory tract infections, or a history of frequent (greater than 2 per year for the last 2 years) infective exacerbations of IPF.
• •Hospitalization within 60 days of screening for an acute exacerbation of IPF (AE-IPF).
• •Chronic heart failure (NYHA class III/IV) or known left ventricular ejection fraction less than 45%.
• •Acute or chronic impairment (other than dyspnea) which limits the ability to comply with study requirements and procedures including the 6MWT.
• •Subject requires hemodialysis, peritoneal dialysis or hemofiltration.
• •Infection with HIV
• •Viral Hepatitis
• •Resting oxygen requirements or \>4 L of nasal canula oxygen needed with exertion